Safety Reading Notes

Read safety context beside the research guide.

The Wake after sleep onset source set includes safety-context rows around safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 37796540

Early human research summary: preliminary human (2)

PubMed For Dummies Article

Wake after sleep onset Evidence Review: the long-form source walk-through

Quick read
  • Wake after sleep onset currently has 20 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 37796540
  • The evidence classes most visible in the row language are preliminary human (19), and insufficient (1). PMID 41698831
  • The study-design language most visible in the row language is Human clinical study (9), double-blind randomized placebo-controlled study (6), and randomized double-blind placebo-controlled crossover trial (5). PMID 37612115
  • The repeated topics are Sleep (5), Wake after sleep onset (2), Sleep onset latency (2), safety, tolerability, sedation, adverse-event, impairment, or formulation-spe... (2), and other mapped categories (9), which tells the reader where to start opening PubMed and DOI links. PMID 38174873

Start with the research question

Wake after sleep onset is built from 20 source-backed evidence row(s) and 6 research source(s). The current evidence classes read as preliminary human (19), and insufficient (1), and the study-design language most often reads as Human clinical study (9), double-blind randomized placebo-controlled study (6), and randomized double-blind placebo-controlled crossover trial (5). PMID 37796540

The row-level question is not simply whether Wake after sleep onset is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Sleep (5), Wake after sleep onset (2), Sleep onset latency (2), safety, tolerability, sedation, adverse-event, impairment, or formulation-spe... (2), and other mapped categories (9). PMID 38174873

Human evidence 15 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 40631525

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 32430450

Mechanistic evidence 0 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 37796540

Limits and uncertainty 5 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 41698831

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 37612115

Where this page has the most source density

The largest bucket surfaced for this page is safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Sleep, which gives readers another way to see what the literature repeatedly circles. PMID 37796540

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 38174873

Bucket chapters: what the literature is circling

safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns

2 research sources 2 rows (508-509) Early human research summary: preliminary human (2)

Wake after sleep onset appears in rows studying safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 37796540

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 37796540

  • Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; durat... PMID 37796540

  • Evidence row 508

    CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human... PMID 37796540

  • Evidence row 509

    CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human... PMID 41698831

Sleep

2 research sources 2 rows (403-409) Early human research summary: preliminary human (2)

Wake after sleep onset appears in rows studying Sleep. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 38174873

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 38174873

  • Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; durat... PMID 37796540

  • Evidence row 403

    CBD studied for Sleep; evidence class: preliminary human (study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 38174873

  • Evidence row 409

    CBD studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 40631525

Sleep

2 research sources 2 rows (500-503) Early human research summary: preliminary human (2)

Wake after sleep onset appears in rows studying Sleep. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 40631525

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 40631525

  • Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; durat... PMID 37796540

  • Evidence row 500

    THC studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 40631525

  • Evidence row 503

    THC studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 32430450

Wake after sleep onset

2 research sources 2 rows (6-17) Early human research summary: preliminary human (2)

Wake after sleep onset appears in rows studying relation to Wake after sleep onset. It currently draws from 2 research source(s), and the reader should inspect the endpoint and model before generalizing. PMID 41698831

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41698831

  • Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; durat... PMID 37796540

  • Evidence row 6

    CBN no detected effect on Wake after sleep onset; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover... PMID 41698831

  • Evidence row 17

    CBN no detected effect on Wake after sleep onset; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20... PMID 37796540

Adverse events

1 research source 15 Early human research summary: preliminary human (1)

Wake after sleep onset appears in rows associated with Adverse events. It currently draws from 1 research source(s), so the direction and study setting need source-level reading. PMID 41698831

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 41698831

  • Evidence row 15

    CBN associated with Adverse events; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: s... PMID 41698831

Anxiety-related outcomes

1 research source 57 Early human research summary: preliminary human (1)

Wake after sleep onset appears in rows studying Anxiety-related outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 38174873

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 38174873

  • Evidence row 57

    CBD studied for Anxiety-related outcomes; evidence class: preliminary human (study design: Human clinical study; outcome measure: anxiety-related outcomes). PMID 38174873

Daytime fatigue

1 research source 18 Early human research summary: preliminary human (1)

Wake after sleep onset appears in rows studying relation to Daytime fatigue. It currently draws from 1 research source(s), and the reader should inspect the endpoint and model before generalizing. PMID 37796540

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 37796540

  • Evidence row 18

    CBN no detected effect on Daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN... PMID 37796540

Nighttime awakenings

1 research source 2 Early human research summary: preliminary human (1)

Wake after sleep onset appears in rows studying relation to Nighttime awakenings. It currently draws from 1 research source(s), and the reader should inspect the endpoint and model before generalizing. PMID 37796540

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 37796540

  • Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; durat... PMID 37796540

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (15 row(s)), mechanistic evidence (0 row(s)), and safety/tolerability context (4 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 37796540

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 38174873

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 38174873
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 40631525
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 32430450

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 37796540

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 38174873

Source-reading checklist for Wake after sleep onset

  1. Open the linked PubMed or DOI record. PMID 37796540
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 41698831
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 37612115
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 38174873
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 40631525

Source Notes

Wake after sleep onset source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  2. Evidence row 3

    CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  3. Evidence row 6

    CBN no detected effect on Wake after sleep onset; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN; outcome measure: polysomnography wake after sleep onset). PMID 41698831

    Evidence class: preliminary human; Study design: randomized double-blind placebo-controlled crossover trial. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  4. Evidence row 7

    CBN decreases Sleep onset latency; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: sleep onset latency). PMID 41698831

    Evidence class: preliminary human; Study design: randomized double-blind placebo-controlled crossover trial. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  5. Evidence row 8

    CBN increases Subjective sleep quality; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: Subjective sleep quality). PMID 41698831

    Evidence class: preliminary human; Study design: randomized double-blind placebo-controlled crossover trial. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  6. Evidence row 9

    CBN increases NREM-2 sleep; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: polysomnography NREM-2 sleep). PMID 41698831

    Evidence class: preliminary human; Study design: randomized double-blind placebo-controlled crossover trial. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  7. Evidence row 14

    CBN decreases Overall sleep disturbance; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: overall sleep disturbance). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  8. Evidence row 15

    CBN associated with Adverse events; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN, or placebo; outcome measure: mild-to-moderate adverse events across arms). PMID 41698831

    Evidence class: preliminary human; Study design: randomized double-blind placebo-controlled crossover trial. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  9. Evidence row 16

    CBN no detected effect on Sleep onset latency; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Sleep onset latency). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  10. Evidence row 17

    CBN no detected effect on Wake after sleep onset; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Wake after sleep onset). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  11. Evidence row 18

    CBN no detected effect on Daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Daytime fatigue). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  12. Evidence row 20

    CBN studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 37612115

    Evidence class: insufficient; Study design: Human clinical study. Source: Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial.
  13. Evidence row 57

    CBD studied for Anxiety-related outcomes; evidence class: preliminary human (study design: Human clinical study; outcome measure: anxiety-related outcomes). PMID 38174873

    Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing.
  14. Evidence row 149

    CBN studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 41698831

    Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  15. Evidence row 403

    CBD studied for Sleep; evidence class: preliminary human (study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 38174873

    Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing.
  16. Evidence row 409

    CBD studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 40631525

    Evidence class: preliminary human; Study design: Human clinical study. Source: Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
  17. Evidence row 500

    THC studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 40631525

    Evidence class: preliminary human; Study design: Human clinical study. Source: Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
  18. Evidence row 503

    THC studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 32430450

    Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial.
  19. Evidence row 508

    CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 37796540

    Evidence class: preliminary human; Study design: Human clinical study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  20. Evidence row 509

    CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 41698831

    Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial